As the US addresses its budget dilemma, the easiest items to cut are those with the longest-term payoff. Research stands out among this group. Biomedical research has already been markedly reduced, and further reductions appear to be in store. As a frequent witness in Congressional hearings on such matters, here I discuss the challenge of assessing the value of investments in biomedical research.
No takes yet. Share an insight, caveat, or question.
Norman R. Augustine (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: